The National Institute for Health and Care Excellence (NICE) has approved ruxolitinib cream (Opzelura, from Incyte) for the treatment of non-segmental vitiligo involving the face in people aged 12 years and older when first-line treatment has failed. Vitiligo is a chronic autoimmune disease in which the skin loses pigment due to the destruction of melanocytes, resulting in symmetrical light or white patches. The cream is applied twice a day and calms the immune system, allowing skin color to be restored. It is the first licensed vitiligo treatment approved for use on the NHS. More than 80,000 adults and teenagers in England can benefit from it. Vitiligo can appear or worsen as a result of illness, stress or skin injury.